A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 4799-4804

  Bobek, Vladimir ^a,b   Kolostova, Katarina ^a   Pinterova, Daniela ^a   Kacprzak, Grzegorz ^b   Adamiak, Jaroslav ^c   Kolodziej, Jerzy ^b   Boubelik, Michael ^a   Kubecova, Martina ^d   Hoffman, Robert M ^e,f  

^a CHARLES UNIVERSITY   (Czech Republic)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Lower Silesian Centre of Lung Diseases   (Poland)

^d CHARLES UNIVERSITY   (Czech Republic)

^e ANTICANCER INC   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

B16 mouse melanoma; Lymph node; Metastasis model; Spontaneous metastasis

Indexed keywords

MELANIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARTILAGE; CELL MIGRATION; DISEASE MODEL; DISTANT METASTASIS; EAR TRANSPLANTATION; FEMALE; LUNG CANCER; LYMPH NODE; LYMPH NODE METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SKIN; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; LYMPHATIC METASTASIS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION;

EID: 78751489030     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Alterman AL, Fornabaio DM and Stackpole CW: Metastatic dissemination of B16 melanoma: pattern and sequence of metastasis. J Natl Cancer Ins 75: 691-702, 1985.
2. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF and Gately MK: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230, 1993.
3. Eberting CL, Shrayer DP, Butmarc J and Falanga V: Histologic progression of B16 F10 metastatic melanoma in C57BL/6 mice over a six week time period: distant metastases before local growth. J Dermatol 31: 299-304, 2004.
4. Eitzman DT, Krauss JC, Shen T, Cui J and Ginsburg D: Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87: 4718-4722, 1996.
5. Fleischmann CM, Stanton GJ and Fleischmann WR Jr.: Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice. Cancer Immunol Immunother 39: 148-154, 1994.
6. Deroose CM, De A, Loening AM, Chow PL, Ray P, Chatziioannou AF and Gambhir SS: Multimodality imaging of tumor xenografts and metastases in mice with combined smallanimal PET, small-animal CT, and bioluminescence imaging. J Nucl Med 48(2): 295-303, 2007.
7. Kobayashi M, Kobayashi H, Pollard RB and Suzuki F: A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160: 5869-5873, 1998.
8. Huber MA, Kraut N, Park JE, Schubert RD, Rettig WJ, Peter RU and Garin-Chesa P: Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol 120: 182-188, 2003.
9. Nathanson SD, Haas GP, Mead MJ and Lee M: Spontaneous regional lymph node metastases of three variants of the B16 melanoma: relationship to primary tumor size and pulmonary metastases. J Surg Oncol 33: 41-45, 1986.
10. Winkelmann CT, Figueroa SD, Rold TL, Volkert WA and Hoffman TJ: Microimaging characterization of a B16-F10 melanoma metastasis mouse model. Mol Imaging 5(2): 105-114, 2006.
11. Shiohara T, Moellmann G, Jacobson K, Kuklinska E, Ruddle NH and Lerner AB: Anti-tumor activity of class II MHC antigenrestricted cloned autoreactive T-cells. II. Novel immunotherapy of B16 melanomas by local and systemic adoptive transfer. J Immunol 138: 1979-1986, 1987.
12. Shrayer DP, Bogaars H, Wolf SF, Hearing VJ and Wanebo HJ: A new mouse model of experimental melanoma for vaccine and lymphokine therapy. Int J Oncol 13: 361-374, 1998.
13. Corbett T: Tumor Models in Cancer Research. Totowa, NJ: Humana Press Inc., pp. 41-71, 2002.
14. Becker JC, Houben R, Schrama D, Voigt H, Ugurel S and Reisfeld RA: Mouse models for melanoma: a personal perspective. Exp Dermatol 19(2): 157-164, 2010.
15. Maguire HC Jr.: Tumor immunology with particular reference to malignant melanoma. Int J Dermatol 14: 3-11, 1975.
16. Nordlund JJ and Gershon RK: Splenic regulation of the clinical appearance of small tumors. J Immunol 114: 1486-1490, 1975.
17. Fidler IJ, Darnell JH and Budmen MB: Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A. Cancer Res 36: 3608-3615, 1976.
18. Fidler I J and Nicolson GL: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst 57: 1199-1202, 1976
19. Valle EF, Zalka AD, Groszek L and Stackpole CW: Patterning of B16 melanoma metastasis and colonization generally relates to tumor cell growth-stimulating or growth-inhibiting effects of organs and tissues. Clin Exp Metastasis 10: 419-429, 1992.
20. Stackpole CW, Alterman AL, Braverman S and Rappaport I: Development of host immunity to phenotypically diverse B16 melanoma clones. Implications for tumor growth and metastasis. Invasion Metastasis 7: 346-366, 1987.
21. Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Investigational New Drugs 17: 343-359, 1999.
22. Price JE: Xenograft models in immunodeficient animals. In: Metastasis Research Protocols, Vol. H, Analysis of Cell Behavior In Vitro and In Vivo. Meth Mol Med. Eds: S.A. Brooks, U. Schumacher, 58: 205-214, 2001.
23. Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD and Giavazzi R: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 55: 460-464, 1994.
24. Ishibashi S, Sonoda K, Fujii K, Ishikawa K, Shiraishi N and Kitano S: A convenient murine model for the study of intra-abdominal lymph node metastasis. Oncol Rep 12(1): 115-118, 2004.
25. Bobek V, Kolostova K, Pinterov D, Boubelik M, Jiang P, Yang M and Hoffman RM: Syngeneic lymph-node-targeting model of green fluorescent protein-expressing Lewis lung carcinoma. Clin Exp Metastasis 21: 705-708, 2004.
26. Yang M, Jiang P, An Z, Baranov E, Li L, Hasegawa S, Al Tuwaijri M, Chishima T, Shimada H, Moossa AR and Hoffman RM: Genetically fluorescent melanoma bone and organ metastasis models. Clin Cancer Res 5: 3549-3559, 1999.
27. Hoffman RM: Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17: 343-359, 1999.
28. An Z, Jiang P, Wang X, Moossa AR and Hoffman RM: Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin Exp Metastasis 17: 265-270, 1999.